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 ABSTRACT 
Objective 
Women with pre-existing (type 1 or type 2) diabetes experience an increased risk of serious 
adverse pregnancy outcomes. It is not known, however, how these risks change between the first 
and second pregnancy, and whether there is an increased risk of recurrence. This study describes 
the absolute risks and recurrence of serious adverse pregnancy outcomes in 220 women with 
pre-existing diabetes. 
 
Research Design and Methods 
440 pregnancies occurring in 220 women with pre-existing diabetes who delivered successive 
singleton pregnancies in the North of England during 1996-2008 were identified from the Northern 
Diabetes in Pregnancy Survey (NorDIP). Predictors of serious adverse outcome were estimated 
by competing-risks regression.  
 
Results 
67 (30.5%) first pregnancies ended in serious adverse outcome, including 14 (6.4%) with 
congenital anomalies and 54 (24.1%) additional fetal or infant deaths. 37 (16.8%) second 
pregnancies ended in serious adverse outcome – half the rate among first pregnancies 
(p=0.0004), including 21 (9.5%) with congenital anomalies and 16 (7.3%) additional fetal or infant 
deaths. Serious adverse outcomes in the second pregnancy occurred twice as frequently in 
women who experienced a previous adverse outcome than those who did not (26.9% vs 12.4%, 
p=0.004), but previous adverse outcome was not associated with preparation for the following 
pregnancy. 
 
Conclusions 
Serious adverse outcomes are less common in the second pregnancies of women with pre-
existing diabetes, though the risk is comparable in those whose first pregnancy ends in adverse 
 outcome. Reducing the risk of recurrence may require more support in the immediate period 
following an adverse pregnancy outcome. 
  
 ABBREVIATIONS 
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 Serious adverse pregnancy outcomes, such as miscarriages, stillbirths, and congenital 
anomalies, are associated with significant psychological distress and parents who experience 
such events are often very anxious about their chances of recurrence.(1; 2) In the general 
population, the risks of miscarriage, stillbirth, and congenital anomaly in the second pregnancy 
are approximately two times greater in women who experienced the same event in their first 
pregnancy,(3-5) although in the absence of a clear genetic or physiological cause the absolute 
risks remain low. 
 
Despite significant improvements in pre-conception and antenatal care, women with pre-existing 
(type 1 or type 2) diabetes still experience substantially increased risks of serious adverse 
pregnancy outcomes, including higher risks of miscarriages,(6) congenital anomalies,(7) 
stillbirths,(8) and infant deaths.(8) Little is known, however, about the absolute risks of these 
outcomes in first and subsequent pregnancies specifically, and whether women with diabetes 
experience the same patterns of recurrence as the general population. Suboptimal glycemic 
control at the start of pregnancy has previously been shown to explain a large proportion of the 
excess risk of congenital anomalies and fetal and infant death.(7; 8) However, the extent that 
inter-pregnancy changes in glycemic control can modify the risk in subsequent pregnancies has 
not been demonstrated. 
 
This study used unique data from the UK’s longest-running survey of women with pre-existing 
diabetes to estimate: 1) preparation for, and change in preparatory behavior between, the first 
and second pregnancies of 220 women with pre-existing diabetes, including the effect of adverse 
outcome in the first pregnancy 2) risk of, change in risk of, and predictors of, serious adverse 
outcome in each pregnancy, including the effect of adverse outcome in the first pregnancy.  
  
 RESEARCH DESIGN AND METHODS 
Population and sample 
The North of England is a distinct geographical region of the UK with a stable population of three 
million and approximately 32,000 births per year (Supplementary Figure 1).  
 
The sample comprises 440 pregnancies occurring in 220 women with pre-existing diabetes who 
completed two successive singleton pregnancies, at any gestational age - regardless of 
pregnancy outcome - in the North of England between 01 January 1996 and 31 December 2008.  
 
Definitions 
Miscarriages are the spontaneous loss of a fetus at ≤23 weeks' gestation. Stillbirths are the 
delivery of a fetus showing no signs of life at ≥24 completed weeks' gestation. Spontaneous fetal 
deaths comprise miscarriages and stillbirths. Infant deaths are the death of a live-born infant aged 
≤1 year. Congenital anomalies are any major chromosomal, genetic, or structural abnormality, as 
defined by the European Surveillance of Congenital Anomalies (EUROCAT) criteria.(9) 
Terminations of pregnancy are the induced loss of a fetus for therapeutic or elective reasons. 
Serious adverse outcomes comprise congenital anomalies, spontaneous fetal deaths, and infant 
deaths. 
 
Data sources 
The Northern Diabetes in Pregnancy Survey (NorDIP) records details of all pregnancies occurring 
in women resident in the region and diagnosed with any type of diabetes at least six months 
before conception. Pregnancies in women with gestational diabetes are not included. Clinicians 
working within the region's nine maternity units collect and supply the NorDIP with information on 
a range of clinical and socio-demographic variables.(10)  
 
 All pregnancies affected by congenital anomaly (regardless of pregnancy outcome) were 
identified from the Northern Congenital Abnormality Survey (NorCAS).(11) All stillbirths and infant 
deaths were identified from the population-based Northern Perinatal Mortality Survey (PMS).(12) 
 
Variables 
All available variables with a hypothesized influence on serious adverse pregnancy outcome were 
obtained from the NorDIP for analyses. Maternal ethnicity, diabetes type, pre-pregnancy history 
of 'clinically diagnosed' nephropathy, neuropathy, and retinopathy, attendance of pre-conception 
care, pre-conception folic acid supplementation (self-reported), smoking during pregnancy (self-
reported), and whether the first antenatal appointment occurred before ten weeks' gestation were 
all analyzed as dichotomous variables. Socioeconomic circumstances were estimated from the 
Index of Multiple Deprivation (IMD, an area-based measure of disadvantage derived from the 
mother's postcode at birth),(13) and analyzed in tertiles of ranks. Year of delivery, maternal age 
at delivery, duration of diabetes, maternal body mass index (BMI, derived from height and weight 
at the first antenatal visit), duration of diabetes, and mean peri-conception glycated hemoglobin 
concentration (A1C) were analyzed as continuous variables. Peri-conception A1C was defined 
as the closest measurement within three months prior to the last menstrual period (available for 
52.9% of pregnancies) or mean first trimester measurement (<14 weeks' gestation) (available for 
82.0% of pregnancies) for women with no pre-conception measurement. Peri-conception A1C 
was considered a reasonable proxy for pre-conception A1C, as first trimester A1C was highly 
correlated with pre-conception A1C (Spearman's correlation coefficient=0.73).(14) Gestational 
age at delivery and at the first antenatal appointment were estimated from information obtained 
at the first ultrasound examination or (rarely) the date of the last menstrual period. Small-for-
gestational-age (SGA, birth weight <10th centile) and large-for-gestational-age (LGA, birth weight 
>90th centile) offspring were identified from their birth weight standardized for fetal sex, parity, and 
gestational age using Scottish birth population standards.(15) 
 
 Four variables were selected as markers of preparation for pregnancy due to their previously 
established associations with pregnancy outcome,(16; 17) and their integration within care 
guidelines for women with pre-existing diabetes in pregnancy:  
1) Peri-conception A1C below 53mmol/mol (7.0%) - recommended by the American 
Diabetes Association (ADA, based in the United States) (18)  
2) Self-reported pre-conception folic acid - the National Institute for Health and Care 
Excellence (NICE, based in England), recommends that women with diabetes take 5mg 
folic acid per day before conception (19)  
3) Attendance at the first antenatal visit before ten weeks' gestation - recommended by 
NICE (19)  
4) Record of attending specialist pre-conception care services - recommended by NICE to 
be offered to all women with pre-existing diabetes. (19) Regional guidelines advise those 
responsible for the routine care of women with diabetes to enquire about plans for 
pregnancy, discuss the benefits of adequate preparation, and refer all those with plans to 
specialist pre-conception care services. 
 
Analysis (aim 1 - preparation for pregnancy) 
The proportion of women achieving each marker of preparation in each pregnancy were 
calculated per 100 total pregnancies. Changes in prevalence and prevalence ratios (PRs) for 
repeat preparatory behavior were estimated within Poisson regression models. The association 
between adverse outcome in the first pregnancy and each marker of preparation in the second 
were examined by logistic regression, with adjustment for baseline behavior.[REF]  
 
Analysis (aim 2 - prevalence and predictors of serious adverse outcome) 
The prevalence of miscarriage, stillbirth, spontaneous fetal death, and congenital anomaly were 
calculated per 100 pregnancies. The prevalence of infant death, delivery by Caesarean section, 
 SGA, and LGA, were calculated per 100 total births. Changes in prevalence and relative risks 
(RRs) of recurrence were estimated within Poisson regression models.  
 
The total probabilities of spontaneous fetal death from 6 weeks, 12 weeks and 24 weeks were 
estimated using a modified Kaplan-Meier approach. Pregnancies entered the 'at risk' period at 
the gestational age of their first antenatal appointment; miscarriages and stillbirths then exited as 
events, and elective terminations of pregnancy were censored, at their gestational age at delivery. 
Live births were modelled as having survived throughout. This approach is robust to distortions 
from late stillbirths by offsetting the per-week risk of adverse outcome against the probability of 
reaching that week of pregnancy. 
 
Predictors of serious adverse outcome in the first and second pregnancy were examined by 
competing-risks regression.(20) Each pregnancy was modelled to be 'at risk' between the 
gestational age of the first antenatal appointment and the gestational age of delivery. The primary 
event was any serious adverse outcome, the competing events were live births or terminations of 
pregnancy without evidence of congenital anomalies. Unadjusted subdistribution hazard ratios 
(SHRs, interpreted like hazard ratios) were calculated for each variable in relation to the risk of 
serious adverse outcome in the first and second pregnancy separately. Adjusted SHRs were 
estimated within a pair of multivariable models, which were constructed using a backwards 
stepwise approach. For each pregnancy, variables with unadjusted p-values>0.5 were entered 
into the model and variables were then removed iteratively (by descending p-value) until only 
those with p<0.1 remained. The shape of association between peri-conception A1C and risk of 
serious adverse pregnancy outcome was explored by locally-weighted scatterplot smoothing 
(LOWESS).(21) Since a J-shaped association was observed, peri-conception A1C was modelled 
by piecewise linear regression with a single knot at the lowest LOWESS value [47mmol/mol 
(6.5%)]. Differences in associations (i.e. interactions) by type of diabetes were not explored due 
to the small number of pregnancies with type 2 diabetes. The absolute risks of serious adverse 
 outcome in the second pregnancy, stratified by outcome in the first pregnancy and categories of 
peri-conception A1C (evaluating at category-specific means) were estimated by taking marginal 
values of a simplified logistic regression model (conditioning only for first-pregnancy outcome and 
peri-conception A1C), estimating 95% confidence intervals (CIs) by the delta method.(22) 
 
Missing data 
Missing data were more likely in women who experienced adverse pregnancy outcomes. All 
calculations were hence evaluated across 100 multiply imputed datasets. Missing values were 
estimated by multivariate imputation by chained equations (MICE) using the variables described 
above, with the addition of A1C in the second and third trimesters. Conditional prevalence 
proportions were estimated by taking marginal values from Poisson regression models, with 95% 
CIs obtained using the delta method.(22) In the absence of missing data, 95% CIs for prevalence 
proportions were estimated using the Clopper-Pearson (Exact) method.(23) Missing values were 
not predicted for gestational age at the first antenatal appointment when required for Cox or 
competing risk regression. No assumptions were made about the missing data pattern. Analyses 
were performed using Stata 11.1 (Statacorp, TX, USA). P<0.05 was considered statistically 
significant. 
 
Ethics approval and research governance  
Newcastle Research Ethics Committee originally granted approval for the NorDIP in 1993. Data 
are now obtained and held with informed consent. 
 
  
 RESULTS 
Description of population 
Of the 220 women with pre-existing diabetes who had two pregnancies recorded during the study 
period, 89% had type 1 diabetes and 95% were white. The median inter-pregnancy interval (the 
time between the end of the first pregnancy and the start of the second) was 1.8 years (IQR: 0.9-
3.0), although this was significantly shorter in women whose first pregnancy ended in a serious 
adverse outcome [1.0 years (IQR: 0.4-2.1) vs 2.0 years (IQR: 1.2-3.2), p<0.0001]. Maternal 
characteristics during the first and second pregnancy are summarized in Supplementary Tables 
1 and 2.  
 
Preparation for pregnancy 
Where not described, hazard ratios, 95% CIs, and p-values can be found in Tables 1-3.  
 
A quarter of women achieved a peri-conception A1C below 53mmol/mol (7.0%) before their first 
and second pregnancies (22.6% and 28.9% respectively), half attended pre-conception care 
(54.1% and 55.5% respectively) and two thirds made their first antenatal visit before ten weeks' 
(61.6% and 66.2% respectively) (Table 1). The proportion of women who consumed folic acid 
supplements before pregnancy increased from 27.1% before the first pregnancy to 43.0% before 
the second pregnancy (p=0.01) (Table 1), although this was not significant after adjusting for year 
of birth (p=0.07). Less than half of women attended both of their first antenatal visits before ten 
weeks' gestation [43.2% (95% CI: 36.5-49.8)], around a third attended pre-conception care in 
both pregnancies [35.0% (95% CI: 28.6-41.4)], and less than a fifth achieved a peri-conception 
A1C below 53mmol/mol or consumed folic acid supplements before both pregnancies [14.4% 
(95% CI: 9.3-19.4) and 15.9% (95% CI: 10.4-21.5) respectively]. 
 
Preparation for pregnancy was correlated between pregnancies. Women who in their first 
pregnancy achieved a peri-conception A1C below 53mmol/mol, consumed folic acid 
 supplements, and attended pre-conception care were respectively 3.33 (p<0.0001), 1.57 
(p=0.04), and 1.45 (p=0.047) times more likely to do so again in the second pregnancy (Table 1).  
 
Experience of a serious adverse outcome in the first pregnancy was not associated with improved 
preparation going into the second pregnancy. Achieving a peri-conception A1C below 
53mmol/mol, attending the first antenatal visit before ten weeks, and attendance of pre-
conception care were, if anything, less likely in the second pregnancy among those who had 
experienced a previous adverse outcome, although none of the associations were significant 
[A1C: OR adjusted for behavior in the first pregnancy, aOR=0.65 (95% CI: 0.29-1.42, p=0.28); 
first appointment before ten weeks: aOR=0.74 (95% CI: 0.40-1.37, p=0.34); attendance of 
preconception care: aOR=0.80 (95% CI: 0.44-1.44, p=0.45)]. There was absolutely no association 
between outcome in the first pregnancy and folic acid consumption in the second [aOR=1.01 
(95% CI: 0.54-1.88, p=0.98)].  
 
  
 Prevalence of serious adverse outcome in either pregnancy 
39.1% (95% CI: 32.6-45.9) of women experienced a serious adverse outcome in at least one 
pregnancy and 8.2% (95% CI: 4.9-12.6) experienced serious adverse outcomes in both 
pregnancies. 
 
Prevalence and predictors of serious adverse outcome in the first pregnancy 
30.5% of first pregnancies were affected by serious adverse outcome. There was no difference 
in prevalence by diabetes type [type 1 vs type 2: 30.8% (95% CI: 24.4-37.8) vs 28.0% (95% CI: 
12.1-49.4), p=0.78]. 17.3% ended in miscarriage, 5.5% in stillbirth, 1.4% in infant death, and 6.4% 
were affected by congenital anomaly (Table 1). Of the 14 first pregnancies affected by congenital 
anomaly, <5 (<35.7% - the exact count is censored to conform to UK disclosure regulations) 
ended in termination of pregnancy. The total probability of spontaneous fetal death (from 6 weeks' 
gestation) was 33.9% (95% CI: 24.7-45.3); from 12 weeks' was 16.1% (95% CI: 11.4-22.4); and 
from 24 weeks' was 6.3% (95% CI: 3.5-11.0).   
 
178 (80.9%, 95% CI: 75.1-85.9) first pregnancies resulted in a registered birth. Of these, 54.5% 
were delivered by caesarean section, 4.5% of offspring were small-for-gestational-age, and 
42.7% were large-for-gestational-age (Table 1).  
 
Non-white ethnicity (p=0.02), pre-pregnancy neuropathy (p<0.0001), increasing maternal age 
(p=0.03) smoking during pregnancy (p=0.01), and increasing peri-conception A1C ≥47 mmol/mol 
(p=0.003) were all independently associated with increased risk of serious adverse outcome in 
the first pregnancy (Table 2).  
 
Prevalence and predictors of serious adverse outcome in the second pregnancy  
16.8% of second pregnancies were affected by serious adverse outcome, 0.55 (p=0.004) times 
the rate in the first pregnancy (Table 1). There was no difference in prevalence by diabetes type 
 [type 1 vs type 2: 16.9% (95% CI: 11.9-22.9) vs 16.0% (95% CI: 4.5-36.1), p=0.91]. The proportion 
of second pregnancies ending in miscarriage (5.5%) and stillbirth (1.4%) respectively were 0.32 
(p=0.0005) and 0.25 (p=0.03) times the rate in the first pregnancy (Table 1). The proportion of 
second pregnancies that ended in infant death (0.5%) or were affected by congenital anomaly 
(9.5%) were not significantly different to the rates observed in the first pregnancy (p=0.28 and 
p=0.24 respectively) (Table 1). Of the 21 second pregnancies affected by congenital anomaly, 
<5 (<23.8%) ended in termination of pregnancy. The total probability of spontaneous fetal death 
(from 6 weeks' gestation) was 11.9% (95% CI: 6.1-22.6); from 12 weeks' was 2.7% (95% CI: 1.1-
6.4); and from 24 weeks' was 1.5% (95% CI: 0.5-4.6).   
 
201 (91.4%, 95% CI: 87.6-95.1) second pregnancies resulted in a registered birth. Of these, 
60.7% were delivered by caesarean section. The proportion of births delivered by Caesarean 
section in the second pregnancy was 2.81 (p<0.0001) times greater in women whose previous 
birth had been delivered by Caesarean section (88.6%); 11.4% (95% CI 5.6-19.9) delivered 
vaginal birth after caesarean (Table 1). 3.5% of births in the second pregnancy were SGA and 
58.2% were LGA (Table 1). The proportion of births in the second pregnancy that were LGA was 
1.55 (p=0.045) times greater in women whose first birth was LGA (69.5%) (Table 1). 
 
Women whose first pregnancy resulted in a serious adverse outcome experienced over twice the 
prevalence of a repeat serious adverse outcome in their second pregnancy than those who did 
not [26.9% vs 12.4%, SHR=2.59 (95% CI: 1.35-4.96), p=0.004] (Table 1 and Table 3). Nearly a 
third of this effect, however, was explained by other explanatory variables. Non-white ethnicity 
(p=0.01), pre-pregnancy nephropathy (p=0.01), and increasing peri-conception A1C≥47 
mmol/mol (p=0.0005) were all independently associated with increased risk of serious adverse 
outcome in the second pregnancy while later year of delivery (p=0.006) was associated with 
decreased risk (Table 3). After adjusting for these and other variables with 0.05<p<0.1, the 
 association between previous adverse outcome and risk in the second pregnancy was no longer 
statistically significant [adjusted SHR, aSHR=1.83 (95% CI: 0.96-3.47), p=0.07] (Table 3).  
 
To establish the relative importance of contemporaneous A1C compared with historical A1C, 
additional analyses were performed with peri-conception A1C in the previous pregnancy. There 
was no crude association between first pregnancy A1C and risk of serious adverse outcome in 
the second [A1C<47mmol/mol: SHR=1.13 (95% CI 0.92-1.40, p=0.25); A1C≥47mmo/mol: 
SHR=1.00 (95% CI: 0.99-1.02, p=0.46)].  After adjusting for other model variables, however, there 
was some suggestion of a lower conditional risk for increasing values of A1C≥47mmol/mol, 
although the effect was outside the nominal significance level [A1C<47mmol/mol: aSHR=1.15 
(95% CI: 0.9-1.44, p=0.24); A1C≥47mmo/mol: aSHR=0.98 (95% CI: 0.95-1.00, p=0.054)].  
 
The absolute risk of serious adverse outcome in the second pregnancy, stratified by outcome in 
the first pregnancy and peri-conception A1C are shown in Table 4.   
 CONCLUSIONS 
Principal findings 
This study describes the preparation for and outcome of the first and second pregnancy in women 
with pre-existing diabetes. The overall risk of serious adverse outcome fell from 30% in the first 
pregnancy to 17% in the second pregnancy. This was predominately attributable to a fall from 
34% to 12% in the probability of spontaneous fetal death.  
 
Women who experienced a serious adverse outcome in their first pregnancy were over two times 
more likely to experience another serious adverse outcome in their second pregnancy, although 
around a third of this was explained by persistent risk factors such as maternal non-white ethnicity 
and higher peri-conception A1C.  
 
A greater proportion of women achieved a favorable peri-conception A1C and consumed folic 
acid supplements before their second pregnancy than their first, though both were still minority 
behaviors. There were no differences in the number who attended pre-conception care, or whose 
first antenatal visit was before 10 weeks' gestation. Achieving a peri-conception A1C below 
53mmol/mol, use of pre-pregnancy folic acid consumption, and attendance of pre-conception care 
were all more likely in the second pregnancy if they had occurred in the first, but there was no 
evidence that experiencing an adverse outcome in the first pregnancy was associated with a 
change in preparation for the second pregnancy. 
 
 
 
Strengths and limitations 
This study benefitted from the North of England’s unique range of long-running population-based 
registers. The NorDIP is England's longest running uninterrupted audit of pregnancies occurring 
in women with pre-existing diabetes and is one of few registers that supports the study of repeated 
 pregnancies in the same mother. Detailed information is gathered before and during each 
pregnancy on a range of clinical and socio-demographic variables. Cases of congenital anomaly 
were identified by the UK’s longest running regional register of congenital anomaly, which 
maintains high ascertainment by receiving information, regardless of pregnancy outcome, from 
multiple sources at any time up to 12 years after birth. The PMS has been collecting information 
on all stillbirths and infant deaths within the region since 1981 and cross-references with mortality 
records from the UK Office for National Statistics. The results of this study are likely to be 
generalizable to any predominately white population with similar standards of peri-conception and 
perinatal care. 
 
Several limitations result from low statistical power. Due to the small absolute number of 
pregnancies ending in any individual outcome specifically, all multivariable analyses used a 
composite variable, serious adverse pregnancy outcome, despite possible heterogeneity. Only 
those associations that apply to all constituent outcomes are likely to have been detected. Due to 
small numbers with type 2 diabetes (n=25), it was not possible to examine whether the identified 
associations differed by diabetes type, although previous studies have found negligible evidence 
of effect modification by diabetes type.(7; 8; 14; 17) Several important exposures also had low 
absolute numbers – most notably maternal ethnicity and the indicators of pre-pregnancy 
microvascular complications. Although women of non-white ethnicity experienced an increased 
risk of serious adverse outcome, the numbers were too small to stratify the second pregnancy 
absolute risks by either ethnicity or pre-pregnancy nephropathy. Lack of statistical significance 
should not be taken as evidence of no effect, as demonstrated by the biologically implausible 
disagreement in the influence of smoking during the first and second pregnancies (Tables 2-3). 
Similarly, the inter-pregnancy differences in the contributions of neuropathy and nephropathy are 
entirely consistent with sampling variation. Data were more likely to be missing in women who 
experienced serious adverse outcomes. MICE was used to reduce any consequent bias, but 
requires all predictors of missingness to be known for complete efficacy. Some individuals with 
 mild microvascular complications may not have been ascertained, since only those who had been 
'clinically diagnosed' (regardless of the method) were recognized. Other potentially-relevant 
exposures, most notably peri-pregnancy medication usage, were not collected.  
 
As with any population-based study, it is unlikely that all pregnancies ending in miscarriage were 
ascertained. Losses before six weeks' are typically undetected,(24) while later losses may be 
recognized but not reported. The earliest recorded miscarriage in a registered pregnancy 
occurred at six weeks', by which time approximately a quarter of women had attended their first 
antenatal appointment. Kaplan Meier scales the denominator to account for differential entry and 
exit times,(25) thus this study should provide an accurate estimate of the risks of spontaneous 
intrauterine death in each pregnancy from six weeks onwards. The total risk of miscarriage from 
conception, however, may be underestimated.  
 
Around half of women in the North of England with pre-existing diabetes do not seek pre-
conception care before getting pregnant.(17) For most of these women, we used first trimester 
A1C values to approximate their pre-conception A1C. Although the two are highly correlated, this 
will have introduced random variation and biased our estimates towards the null. A1C provides 
an incomplete profile of overall glycemic control as it provides no information on potentially salient 
glycemic excursions or hypoglycemic episodes.(26) Unfortunately, continuous glucose 
monitoring, which might permit such investigations, is not yet routinely available in the UK.  
 
Comparison with other studies 
This study is the first to explore the risk of recurrence of adverse pregnancy outcomes in women 
with pre-existing diabetes, and to describe the absolute risks in first and second pregnancies 
specifically. Nevertheless, there are analogous observations in the general population. The 
relative risks of recurrence for both congenital anomalies (at 1.55, 95% CI 0.40-5.99) and fetal or 
infant death (at 2.45, 95% CI 0.96-6.26), for example, were highly consistent with the doubling of 
 risk seen in the general population.(3-5) Across both pregnancies, the prevalence of congenital 
anomaly [8.0% (95% CI: 5.4-10.5)], stillbirth [3.4% (1.7-5.1)], and infant death [1.2% (<0.1-2.4)] 
were all consistent with previous observations in larger samples from the same population [7.7% 
(95% CI: 6.5-9.1), 2.7% (1.9-3.6), and 0.7% (0.3-1.2) respectively].(7; 8) The proportion of 
pregnancies ending in miscarriages [11.4% (8.4-14.3)] was consistent with the 5-20% that is 
typically reported in women with diabetes.(27-29)  
 
Comparisons are more problematic for the change in risk between the first and second pregnancy, 
due to large differences in the profile of primiparous and multiparous women.(30) This likely 
explains the discrepancy between the current study, and a previous cross-sectional analysis, in 
which no association was found between parity and the risk of stillbirth.(8) Even in longitudinal 
studies, the true attributable risk of parity may be masked by changes in other risk factors (such 
as maternal age and BMI) between the first and subsequent pregnancy.(31) Nevertheless, it is 
broadly recognized that the prevalence of serious adverse pregnancy is greater among first 
pregnancies than subsequent. In the general population, Flenady et al's meta-analysis estimated 
that the risk of stillbirth was 1.40 (95% CI: 1.33-1.42) times higher among primiparous women 
than multiparous.(32) Though apparently much smaller than we observed (RR, for primiparity vs 
multiparity: 4.02, 95% CI: 1.15-14.04), the difference is consistent with normal sampling variation 
(p=0.10). A similar pattern was apparent for miscarriage, with the crude RR for the current study 
(3.17, 95% CI: 1.70-5.90) being higher, but not significantly (p=0.07), than in a UK sample of 
women of reproductive age (1.75, 95% CI: 1.42-2.14 comparing first and second pregnancies 
specifically). We did not find a relationship between pregnancy order and the risk of congenital 
anomalies, despite it previously having been observed in the general population.(33) This may 
reflect our modest sample size, or the aforementioned complications of comparing longitudinal 
with cross-sectional data.  
Implications and Conclusions 
 Women with pre-existing diabetes continue to experience very high risks of serious adverse 
pregnancy outcomes. In the first pregnancy, nearly a third [30.5% (95% CI: 24.4-37.0)] were 
affected. In the second, as in the general population, pregnancy outcomes were more favorable, 
with a much lower risk among those who had not experienced an adverse outcome in their first 
[12.4% (7.6-18.7]. This was not explained by changes in any of the known risk factors, and may 
instead reflect constitutionally higher risks in the first pregnancy, such as pregnancy-induced 
hypertension and intrauterine growth restriction.[REF] Among those whose first pregnancy was 
affected by serious adverse outcome, the risk in the second pregnancy remained very high [26.9% 
(16.8-39.1)]. Around a third of this was explained by persistent, and known, risk factors. Adverse 
outcomes were more common in both pregnancies among women from minority ethnic groups, 
consistent with previous observations in pregnant women with pre-existing diabetes.(34) This 
may reflect genetic factors or it may represent enduring environmental or behavioral influences. 
Preparation for pregnancy is particularly poor in non-white women in the North of England,(17) 
indicating these women urgently require additional or alternative methods of support, such as 
community-based approaches.(35) We observed the same J-shaped association between peri-
conception A1C and adverse outcome that has been identified before,(36) with a steep increase 
in risk of 2-3% per mmol/mol from 47mmol/mol (equivalent to a doubling per 25-35mmol/mol).This 
reinforces the benefits of good, though not overly strict, glycemic control before conception.(8) 
Notably, while peri-conception A1C levels were correlated across both pregnancies, only current 
values were associated with outcome,  suggesting this may be a causal, and therefore reversible, 
association. However, after adjusting for current values, there was some suggestion of a residual 
protective effect of A1C in the previous pregnancy, indicating the highest risk may be in women 
whose glycemic control deteriorates substantially between pregnancies. 
 
Preparation for pregnancy among our sample of women with diabetes was poor. Only a quarter 
managed the pre-conception A1C target or took folic acid supplements before their first 
pregnancy, and only just over a half attended pre-conception care or had their first antenatal 
 appointment before ten weeks'. Although favorable preparation in the first pregnancy was broadly 
predictive of repeat behavior in the second pregnancy, this exposes a disheartening converse. 
Women whose first pregnancy ended in a serious adverse pregnancy outcome did not appear to 
change their preparatory behavior for the subsequent pregnancy. Given the short inter-pregnancy 
interval [1.0 years (IQR: 0.4-2.1)] there is clearly a narrow period for intervention and many of the 
circumstances that inhibited planning and preparation for the first pregnancy are likely to remain 
for the second. This motivates need for a change in approach, such as providing intensive 
postnatal support after an adverse event, covering various aspects of care such as control, 
contraception use, and general well-being.(35) Such an intervention, however, would have to be 
carefully balanced against the family's psychological needs, given the negative impact of 
discussing future pregnancies during a period of grief.(37) Regardless, since pre-conception care 
was equally poor across both pregnancies, changes (or greater choice) may be needed in the 
style and setting of support for all women with diabetes.(35) The barriers to improved pregnancy 
planning and preparation are multifaceted and complex,(38) but further progress is urgently 
needed to reduce the risk of recurrent tragedy in women with diabetes.  
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 Table 1: Pregnancy preparation and outcome in first and second pregnancies, and prevalence ratios/relative risks for repeat 
behavior/recurrence of adverse outcomes 
 
Variable 
Prevalence proportion 
(95% CI) [n/N] 
Relative change in 
summary 
prevalence  
 (95% CI) [p-value] 
Conditional prevalence in second 
pregnancy (95% CI) [n/N] Prevalence ratio/ 
relative risk 
(95% CI) [p-value] First pregnancy 
Second 
pregnancy 
Also in first 
pregnancy 
Only in second 
pregnancy 
Preparation for pregnancy   
    
Peri-conception A1C 
<53mmol/mol (7.0%) 
22.6% (16.5-28.6) 
[50/220]* 
28.9% (22.6-35.2) 
[64/220]* 
1.32 (0.89-1.95) 
[p=0.17] 
63.2% (40.4-86.1) 
[32/50]* 
18.8% (11.8-25.8) 
[32/170]* 
3.33 (1.97-5.65) 
[<0.0001]* 
Pre-conception folic acid 
27.1% (20.4-33.8) 
[60/220]* 
43.0% (36.2-49.9) 
[95/220]* 
1.55 (1.11-2.18) 
[p=0.01] 
58.7% (38.6-78.8) 
[35/60]* 
37.4% (27.5-47.2) 
[60/160]* 
1.57 (1.01-2.43) 
[p=0.04]* 
First antenatal visit <10 weeks'  
61.6% (55.1-68.2) 
[136/220]* 
66.2% (59.9-72.5) 
[146/220]* 
1.08 (0.85-1.36) 
[p=0.53] 
70.0% (55.9-84.2) 
[95/136]* 
60.1% (43.4-76.7) 
[50/84]* 
1.17 (0.83-1.64) 
[p=0.38]* 
Attended pre-conception care 
54.1% (47.3-60.8) 
[119/220] 
55.5% (48.6-62.1) 
[122/220] 
1.03 (0.80-1.32) 
[p=0.85] 
64.7% (50.3-79.2) 
[77/119] 
44.6% (31.5-57.6) 
[45/101] 
1.45 (1.01-2.10) 
[p=0.047] 
Serious adverse outcome   
 
   
Any serious adverse outcome 
30.5% (24.4-37.0) 
[67/220] 
16.8% (12.1-22.4) 
[37/220] 
0.55 (0.37-0.83) 
[p=0.004] 
26.9% (16.8-39.1) 
[18/67] 
 12.4% (7.6-18.7) 
[19/153] 
2.16 (1.14-4.12) 
[p=0.02] 
Congenital anomaly  
 6.4% (3.5-10.4) 
[14/220] 
 9.5% (6.0-14.2) 
[21/220] 
1.50 (0.76-2.95) 
[p=0.24] 
14.3% (1.8-42.8) 
[2/14] 
9.2% (5.6-14.0) 
[19/206] 
1.55 (0.36-6.65) 
[p=0.56] 
Spontaneous fetal deaths, 
infant deaths, or terminations of 
pregnancy for fetal anomaly 
25.5% (19.8-31.7) 
[56/220] 
10.5% (6.7-15.3) 
[23/220] 
0.41  (0.25-0.67) 
[p=0.0003] 
19.6% (10.2-32.4) 
[11/56] 
7.3% (3.8-12.4) 
[12/164] 
2.68 (1.26-5.74) 
[p=0.009] 
       
 Fetal or infant death in 
normally-formed offspring† 
24.1% (18.6-30.3) 
[53/220] 
 7.3% (4.2-11.5) 
[16/220] 
0.30 (0.17-0.53) 
[p<0.0001] 
13.2% (5.5-25.3) 
[7/53] 
5.4% (2.5-10.0) 
[9/167] 
2.45 (0.91-6.58) 
[p=0.08] 
Spontaneous fetal death† 
23.7% (17.4-28.8) 
[50/220] 
 6.8% (3.9-11.0) 
[15/220] 
0.30 (0.17-0.53) 
[p<0.0001] 
14.0% (5.8-26.7) 
[7/50] 
 4.7% (2.1-9.1) 
[8/170] 
2.98 (1.08-8.20) 
[p=0.04] 
Miscarriage† 
17.3% (12.5-22.9) 
[38/220] 
5.5% (2.8-9.3) 
[12/220] 
0.32 (0.17-0.60) 
[p=0.0005] 
 5.3% (0.6-17.7) 
[2/38] 
5.3% (2.7-9.9) 
[10/182] 
0.96 (0.21-4.37) 
[p=0.96] 
Stillbirth† 
5.5% (2.8-9.3) 
[12/220] 
1.4% (0.3-3.9) 
[3/220] 
0.25 (0.07-0.89) 
[p=0.03] 
0.0% (0.0-26.5) 
[0/12] 
1.4% (0.3-4.2) 
[3/208] 
- 
Infant death† 
1.4% (0.3-3.9) 
[3/220] 
 0.5% (0.1-2.5) 
[1/220] 
0.29 (0.03-2.74) 
[p=0.28] 
0.0% (0.0-70.8) 
[0/3] 
0.5% (0.0-2.5) 
[1/217] 
- 
Other outcomes (births only)‡    
 
   
Delivery by Caesarean section‡ 
54.5% (46.9-62.0) 
[97/178] 
60.7% (53.6-67.5) 
[122/201] 
1.05 (0.79-1.41) 
[p=0.71] 
88.6% (80.1-94.4) 
[78/88]§ 
31.6% (21.4-43.3) 
[24/76]§ 
2.81 (1.78-4.44) 
[p<0.0001]§ 
Small for gestational age‡ 
4.5% (2.0-8.7) 
[8/178] 
3.5% (1.4-7.0) 
[7/201] 
0.86 (0.29-2.55) 
[p=0.78] 
14.3% (0.4-57.9) 
[1/7]§ 
2.5% (0.7-6.4) 
[4/157]§ 
5.61 (0.63-50.17) 
[p=0.12]§ 
Large for gestational age‡ 
42.7% (35.3-50.3) 
[76/178] 
58.2% (51.1-65.1) 
[117/201] 
1.04 (0.78-1.39) 
[p=0.77] 
69.5% (59.2-78.5) 
[66/95]§ 
44.9% (32.9-57.4) 
[31/69]§ 
1.55 (1.01-2.37) 
[p=0.045]§ 
 
*Prevalence proportions were estimated over 100 multiply imputed datasets with confidence intervals determined from the 
analytically derived variance estimator. Counts represent the rounded average across the 100 datasets and should be considered 
indicative. †Cases exclude offspring with congenital anomalies ‡Sample restricted to pregnancies resulting in registered births (i.e. 
live-birth or stillbirths) and includes pregnancies complicated by congenital anomaly §Rates calculated from sample of 164 women 
with two successive births 
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Table 2: Predictors of serious adverse outcome in the first pregnancy  
 
Variable 
Unadjusted SHR  
(95% CI) 
p-value 
(overall) 
Adjusted SHR  
(95% CI) 
p-value 
(overall) 
Non-modifiable variable     
Type of diabetes   
Not entered (p>0.5) 
 
   Type 1 Reference   
   Type 2 1.01 (0.45-2.26) 0.98  
Maternal ethnic origin     
   White Reference  Reference  
   Non-white 3.23 (1.25-8.37) 0.02 3.18 (1.19-8.47) 0.02 
Index of Deprivation   
Not entered (p>0.5) 
 
   Tertile 1 (most deprived) 1.14 (0.63-2.06) 0.67  
   Tertile 2 Reference (0.52)  
   Tertile 3 (least deprived) 0.79 (0.42-1.49) 0.47  
Pre-pregnancy nephropathy   
Not entered (p>0.5) 
 
   Yes 1.02 (0.24-4.32) 0.98  
   No Reference   
Pre-pregnancy neuropathy     
   Yes 2.77 (1.83-4.20) <0.0001 4.65 (2.23-9.68) <0.0001 
   No Reference  Reference  
Pre-pregnancy retinopathy   
Eliminated (p<0.1) 
 
   Yes 0.57 (0.23-1.41) 0.22  
   No Reference   
Year of delivery (year) 0.94 (0.86-1.02) 0.16 0.93 (0.85-1.01) 0.08 
Duration of diabetes (years) 0.97 (0.93-1.01) 0.11 Eliminated (p<0.1)  
Maternal age (years) 1.04 (0.98-1.09) 0.20 1.07 (1.01-1.13) 0.03 
Potentially modifiable variable     
Smoked during pregnancy     
   Yes 1.78 (1.02-3.11) 0.042 2.25 (1.18-4.29) 0.01 
   No Reference  Reference  
Pre-conception folic acid   
Eliminated (p<0.1) 
 
   Yes 0.75 (0.35-1.60) 0.45  
   No Reference   
First antenatal visit < 10 weeks   
Not entered (p>0.5) 
 
   Yes 0.98 (0.53-1.81) 0.94  
   No Reference   
Attended pre-conception care   
Not entered (p>0.5) 
 
   Yes 1.09 (0.66-1.81) 0.73  
   No Reference   
Body mass index (Kg/m2) 1.02 (0.97-1.06) 0.49 Eliminated (p<0.1)  
Peri-conception A1C (mmol/mol)  (0.04)  (0.02) 
   <47mmol/mol (<6.5%) 1.00 (0.91-1.09) 0.95 1.00 (0.92-1.09) 0.93 
   ≥47mmol/mol (≥6.5%) 1.01 (1.00-1.02) 0.01 1.02 (1.01-1.03) 0.003 
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Table 3: Predictors of serious adverse outcome in the second pregnancy 
 
Variable 
Unadjusted SHR  
(95% CI) 
p-value 
(overall) 
Adjusted SHR  
(95% CI) 
p-value 
(overall) 
Non-modifiable variable     
Outcome in the first pregnancy     
   Normally-formed live birth Reference  Reference  
   Miscarriage, stillbirth or CA 2.59 (1.35-4.96) 0.004 1.83 (0.96-3.47) 0.07 
Type of diabetes   
Not entered (p>0.5) 
 
   Type 1 Reference   
   Type 2 0.89 (0.31-2.52) 0.83  
Maternal ethnic origin     
   White Reference  Reference  
   Non-white 2.84 (1.00-8.08) 0.0498 3.38 (1.19-9.61) 0.02 
Index of Deprivation   
Not entered (p>0.5) 
 
   Tertile 1 (most deprived) 1.10 (0.49-2.50) 0.81  
   Tertile 2 Reference (0.96)  
   Tertile 3 (least deprived) 1.12 (0.50-2.51) 0.78  
Pre-pregnancy nephropathy     
   Yes 2.76 (1.08-7.10) 0.03 3.37 (1.23-9.26) 0.02 
   No Reference  Reference  
Pre-pregnancy neuropathy     
   Yes 1.35 (0.20-9.05) 0.76 Not entered (p>0.5)  
   No Reference    
Pre-pregnancy retinopathy   
Not entered (p>0.5) 
 
   Yes 1.23 (0.55-2.78) 0.62  
   No Reference   
Year of delivery (year) 0.87 (0.78-0.96) 0.007 0.84 (0.76-0.94) 0.002 
Duration of diabetes (years) 0.97 (0.93-1.02) 0.28 Eliminated (p<0.1)  
Maternal age (years) 0.98 (0.92-1.03) 0.39 Eliminated (p<0.1)  
Potentially modifiable variable     
Smoked during pregnancy     
   Yes 1.24 (0.55-2.76) 0.61 Not entered (p>0.5)  
   No Reference    
Pre-conception folic acid   
Not entered (p>0.5) 
 
   Yes 1.14 (0.56-2.32) 0.72  
   No Reference   
First antenatal visit < 10 weeks   
Eliminated (p<0.1) 
 
   Yes 0.66 (0.32-1.35) 0.25  
   No Reference   
Attended pre-conception care     
   Yes 1.76 (0.88-3.53) 0.11 1.83 (0.92-3.64) 0.09 
   No Reference  Reference  
Inter-pregnancy interval (years) 0.93 (0.74-1.17) 0.55 Not entered (p>0.5)  
Body mass index (Kg/m2) 0.95 (0.88-1.03) 0.21 Eliminated (p<0.1)  
Peri-conception A1C (mmol/mol)  (0.0005)  (0.003) 
   <47mmol/mol (<6.5%) 0.94 (0.80-1.11) 0.47 0.94 (0.79-1.11) 0.45 
   ≥47mmol/mol (≥6.5%) 1.03 (1.01-1.04) 0.0001 1.03 (1.01-1.04) 0.0008 
  31 
Table 4: Absolute risk of serious adverse outcome in the second pregnancy, stratified by 
outcome in the first pregnancy, and peri-conception A1C  
 
Outcome in  
first pregnancy 
Peri-conception 
A1C  
Risk of serious adverse outcome  in the 
second pregnancy (95% CI) 
mmol/mol DCCT % Percentage As fraction 
Live birth and  
infant alive at  
aged one year 
Total prevalence → 12.4 (7.6-18.7) 1 in 8 (5-13) 
<53 <7.0 6.5 (2.1-10.9) 1 in 15 (9-47) 
53-63 7.0-7.9 8.3 (3.6-13.0) 1 in 12 (8-28) 
64-74 8.0-8.9 11.1 (5.8-16.4) 1 in 9 (6-17) 
75-85 9.0-9.9 14.9 (8.2-21.6) 1 in 7 (5-12) 
≥86 ≥10 25.9 (11.8-40.1) 1 in 4 (2½-8) 
Spontaneous fetal 
death, infant death, 
or congenital 
anomaly 
Total prevalence → 26.9 (16.8-39.1) 1 in 4 (2½-6) 
<53 <7.0 15.2 (5.3-25.0) 1 in 7 (4-19) 
53-63 7.0-7.9 18.9 (8.6-29.2) 1 in 5 (3-12) 
64-74 8.0-8.9 24.3 (13.3-35.2) 1 in 4 (3-8) 
75-85 9.0-9.9 31.1 (18.6-43.6) 1 in 3 (2½-5) 
≥86 ≥10 47.3 (28.0-66.6) 1 in 2 (1½-4) 
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Supplemental Table 1: Descriptive statistics for study participants (continuous variables) 
 
Continuous variable 
First pregnancy  (N=220) Second pregnancy (N=220) 
n Range 
Median 
(IQR) 
n Range 
Median 
(IQR) 
Gestation at first antenatal visit  
   (weeks)  
213 1-34 9 (7-11) 219 3-22 8 (6-11) 
Gestation at delivery  
   (weeks) 
220 4-40 36 (32-38) 220 6-41 37 (35-38) 
Duration of diabetes  
   (years) 
219 1-27 9 (4-15) 219 2-30 12 (7-18) 
Maternal age at delivery  
   (years) 
220 15-40 26 (21-30) 220 17-46 29 (24-33) 
Maternal body mass index  
   (kg/m2) 
157 17-60 26 (23-29) 172 18-58 26 (23-30) 
Peri-conception A1C  
   (mmol/mol) 
187 25-187 65 (54-83) 190 29-143 62 (51-77) 
Peri-conception A1C  
   (%) 
187 4.4-19.3 8.1 (7.1-9.7) 190 4.8-15.2 7.8 (6.8-9.2) 
 Both pregnancies  (N=220)    
Inter-pregnancy interval  
   (years) 
220 <0.1-10.1 1.8 (0.9-3.0)    
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Supplementary Table 2: Descriptive statistics for study participants (categorical variables) 
 
Categorical variable 
First pregnancy  (N=220) Second pregnancy (N=220) 
n % n % 
Index of Deprivation     
   Tertile 1 (most deprived) 69 31.4 69 31.4 
   Tertile 2 72 32.7 73 33.2 
   Tertile 3 (least deprived) 79 35.9 78 35.5 
Pre-pregnancy nephropathy     
   Yes 7 3.2 10 4.6 
   No 213 96.8 210 95.5 
Pre-pregnancy neuropathy     
   Yes 1 0.5 4 1.8 
   No 219 99.6 216 98.2 
Pre-pregnancy retinopathy     
   Yes 26 11.8 47 73.6 
   No 186 84.6 162 21.4 
   Missing 8 3.6 11 5.0 
Smoked during pregnancy     
   Yes 46 20.9 47 21.4 
   No 152 69.1 156 70.9 
   Missing 22 10.0 17 7.7 
Pre-conception folic acid     
   Yes 51 23.2 89 40.5 
   No 138 62.7 117 53.2 
   Missing 31 14.1 14 6.4 
First antenatal visit < 10 weeks     
   Yes 131 59.6 145 65.9 
   No 82 37.3 74 33.6 
   Missing 7 3.2 1 0.5 
Attended pre-conception care     
   Yes 119 54.1 122 55.5 
   No 101 45.9 98 44.6 
Year of delivery*     
   1996-1999 79 35.9 30 13.6 
   2000-2004 105 47.7 77 35.0 
   2005-2008 36 16.4 113 51.4 
 Both pregnancies (N=220)   
Diabetes type     
   Type 1 195 88.6   
   Type 2 25 11.4   
Ethnicity     
   White 209 95.0   
   Non-white 11 5.0   
 
*Year of delivery was analyzed as a continuous variable, but is presented in categories to 
aid comprehension 
